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Abstract Cytokine-dependent regulation of tissue inhibitors of
metalloproteinases (TIMPs) expression provides an important
mechanism for controlling the activity of matrix metallopro-
teinases. We present data indicating that during inflammatory
processes TIMP-1 and TIMP-3 may be involved in the
proteolytic remodeling of subendothelial basement membrane
of the brain microvascular system, a key step during leukocyte
migration into the brain perivascular tissue. In brain endothelial
cells the expression of TIMP-1 is dramatically up-regulated by
major proinflammatory cytokines, with the combination of
interleukin-1L (IL-1L) and tumor necrosis factor-K (TNFK)
exhibiting the strongest synergistic stimulation. Simultaneously,
IL-1L/TNFK almost completely blocks TIMP-3 expression.
Both synergistic effects are dose-dependent within the concentra-
tion range 0.05^5 ng/ml of both cytokines and correlate with the
expression of inducible nitric oxide synthase, an endothelial cell
activation marker. Down-regulation of TIMP-3 expression is
also detected in astrocytes treated with TNFK or IFN-Q, whereas
oncostatin M as well as TNFK up-regulate TIMP-1 mRNA
level. We propose that the cytokine-modified balance between
TIMP-1 and TIMP-3 expression provides a potential mechanism
involved in the regulation of microvascular basement membrane
proteolysis.
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1. Introduction
Endothelial cells actively participate in in£ammatory reac-
tions. In response to in£ammatory cytokines they undergo
profound alteration of functions referred to as endothelial
cell activation [1]. A major alteration of endothelial cell char-
acteristics upon activation is their acquisition of adhesiveness
for leukocytes mediated by increased expression of some con-
stitutive cell adhesion molecules as well as synthesis of new
surface proteins such as E-selectin or VCAM-1. Integrin-de-
pendent adhesion and transmigration of leukocytes through
the endothelial cell layer have been extensively studied, where-
as only limited information is available on the mechanisms
which control proteolytic remodeling of subendothelial base-
ment membrane required for further steps of leukocyte migra-
tion [2].
Unlike interstitial extracellular matrix (ECM) composed
predominantly of collagen types I, II, and III, basement mem-
branes contain collagen types IV and V structurally organized
in a non-¢brillar, multilayer network [3]. The major group of
enzymes controlling basement membrane ECM turnover are
gelatinases (MMP-2 and MMP-9), a subclass of the matrix
metalloproteinase (MMP) family including also collagenases,
stromelysins, and membrane-type MMPs (MT-MMPs).
MMPs are usually secreted as inactive proenzymes and can
be activated extracellularly by other proteinases including ac-
tive MMPs themselves [4]. Several physiological mechanisms
prevent uncontrolled MMP activation. One of these is binding
of MMPs by tissue inhibitors of metalloproteinases (TIMPs)
[5]. By inhibition of MMP activity, TIMPs contribute to the
regulation of ECM remodeling associated with various phys-
iological and pathological conditions [6].
Apart from the role in the regulation of ECM proteolysis,
at sites of in£ammation MMPs and TIMPs may contribute to
important immunoregulatory processes such as cytokine and
cytokine receptor turnover [7]. For example, MMP-1, -2, -3,
and -9 have been shown to degrade interleukin-1L (IL-1L) ;
and this can be e¡ectively blocked by TIMP-1 [8]. Further-
more, it has been recently described that TIMP-3 is capable of
inhibiting tumor necrosis factor-K (TNFK) converting en-
zyme, a metalloproteinase which belongs to the ADAM (A
disintegrin and metalloproteinase) family of proteins [9].
Apart from the inhibition of TNFK precursor processing,
TIMP-3 can also down-regulate shedding of TNF receptor
p55, IL-6 receptor gp80 and L-selectin [10^12], however pro-
teinases involved in the later processes remain unknown.
Major proin£ammatory cytokines (IL-1L, TNFK and inter-
feron-Q (IFN-Q)) as well as IL-6 family cytokines (IL-6 and
oncostatin M (OSM)) are, in turn, important regulators of
MMP and TIMP expression [13]. In this paper we describe
a dramatic reprogramming of TIMP-1 and TIMP-3 expres-
sion pro¢les in cytokine-stimulated brain endothelial cells and
astrocytes, two major cell types which contribute to the syn-
thesis and turnover of the brain microvascular basement
membrane. These ¢ndings suggest that TIMP-1 and TIMP-3
may play distinct roles in the regulation of local in£ammatory
processes in the central nervous system.
FEBS 21791 29-3-99
0014-5793/99/$20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 3 2 3 - 3
*Corresponding author. Fax: (1) (706) 542-3719.
E-mail: marcinb@arches.uga.edu
1Present address: University of Georgia, Department of Biochemistry
and Molecular Biology, Life Sciences Bldg., Athens, GA 30602, USA.
Abbreviations: ECM, extracellular matrix; EtBr, ethidium bromide;
FCS, fetal calf serum; iNOS, inducible nitric oxide synthase; OSM,
oncostatin M; MBE, murine brain microvascular endothelial cells;
MMP, matrix metalloproteinases; MS, multiple sclerosis; MT-MMP,
membrane-type MMP; Stat, signal transducer and activator of
transcription; TIMP, tissue inhibitor of metalloproteinases
FEBS 21791 FEBS Letters 448 (1999) 9^14
2. Materials and methods
2.1. Cell culture
Primary astrocyte cultures were prepared by multiple passaging of
the mixed brain cell cultures established from cortical tissue of 12^14
week old Wistar rats [14]. The cells were cultured in MEM (Life
Technologies Ltd., Paisley, UK) containing 1% glucose, 1 mM sodium
pyruvate, 2 mM glutamine and 10% fetal bovine serum. Prior to
con£uence the cell culture £asks were shaken overnight and non-ad-
herent cells were discarded. The remaining cells were repassaged by
trypsinization (dilution 1:4). This process was repeated until the cul-
tures were s 98% pure astrocytes as judged by immunocytochemistry
analysis for glial ¢brillary acidic protein (3^4 passages). Passages 5^10
were used for the experiments. Cultures of murine brain microvascu-
lar endothelial cells (MBE), a gift from Dr. R. Auerbach (Madison,
WI, USA) were s 98% pure as judged by the assay for VCAM-1-
positive cells and were additionally characterized in several previously
published studies [15]. The cells were cultured in medium consisting of
DMEM, 20% fetal calf serum (FCS) (both from Life Technologies
Ltd., Paisley, UK), endothelial cell growth supplement (30 mg/ml),
2 mM glutamine, penicillin (100 U/ml) and streptomycin (100 U/ml)
(all from Sigma Chemical Co., St. Louis, MO, USA). Passages 8^12
were used in the experiments. Human hepatoma HepG2 cells, a gift of
Dr. H. Baumann (Bu¡alo, NY, USA), were cultured in DMEM sup-
plemented with 10% FCS and antibiotics.
2.2. Cytokines and cell stimulation
Cells were stimulated with 0.05, 0.5 or 5 ng/ml rhIL-1L (1.2U108 U/
mg), 25 ng/ml rhOSM (4.7U107 U/mg) (both a gift from Immunex
Corp., Seattle, WA, USA), 0.05, 0.5 or 5 ng/ml rhTNFK (purchased
from RpD Systems, Minneapolis, MN, USA) and 200 U/ml rmIFN-Q
(Life Technologies Ltd., Paisley, UK).
2.3. RNA preparation and Northern blot analysis
MBE cells and astrocytes were grown to 80^90% con£uence as
described above. Media were then changed into RPMI 1640 (Life
Technologies Ltd., Paisley, UK) containing 2% of heat-inactivated
FCS (MBE cells) or DMEM containing 2% heat-inactivated FCS
(astrocytes), 2 mM glutamine and antibiotics. The tested cytokines
were then added and cells were incubated for an additional 18 h.
Total RNA was prepared using the phenol extraction method [15].
5 Wg samples of RNA were subjected to formaldehyde gel electro-
phoresis using standard procedures [16] and transferred to Hybond-
N membranes (Amersham Life Science, Little Chalfont, UK), accord-
ing to the manufacturer’s instructions. Ethidium bromide-stained ¢l-
ters were photographed prior to hybridization to show the equal load-
ing of RNA. 28S and 18S rRNA visualized in this procedure were
used as indicators of gel loading since the expression of some refer-
ence genes used to standardize Northern blotting data, especially
glyceraldehyde 3-phosphate dehydrogenase [17], may be considerably
altered by cytokines in MBE cells. Filters were prehybridized at 68‡C
for 3 h in 10% dextran sulfate, 1 M sodium chloride and 1% SDS, and
hybridized in the same solution with cDNA probes speci¢c for the
murine TIMP-1 and TIMP-3, murine macrophage iNOS (a gift from
Drs. Q.-W. Xie and C. Nathan, New York, NY, USA), and murine
VCAM-1 (a gift from Dr. L. Osborn, Cambridge, MA, USA) labeled
by random priming using Megaprime DNA labeling system (Amer-
sham). After hybridization, non-speci¢cally bound radioactivity was
removed by washing in 2USSC at room temperature, followed by two
washes in 2USSC/1% SDS at 68‡C for 20 min. The blots were then
subjected to autoradiography at 370‡C.
2.4. Nuclear extract preparation and gel retardation assays
Cells were grown as described previously to 70^80% con£uence and
fresh media containing 2% FCS were then added. After 24 h cells were
stimulated for 15 min with indicated factors. Nuclear extracts were
prepared as described [18,19]. A double stranded DNA fragment con-
taining the high a⁄nity sis-inducible element of human c-fos promoter
(SIE) [20] was labeled by ¢lling in 5P protruding ends with Klenow
enzyme using [K-32P]dCTP (3000 Ci/mmol). Gel retardation assays
were carried out according to published procedures [21,22]. 2^5 Wg
of nuclear extracts and approximately 10 fmol (10 000 cpm) of probe
were used. Some samples were incubated in the presence of a 50-fold
molar excess of speci¢c unlabeled oligonucleotide probe as a compet-
itor. Protein-DNA complexes were separated in a 4.5% polyacryl-
amide gel in 0.5UTBE. The gels were dried and exposed to X-ray
¢lm at 370‡C.
2.5. Nitrite assay
Assays for nitrate production were performed as described previ-
ously [23]. Cells cultured in RPMI 1640 supplemented with 2% FCS
and antibiotics were stimulated with indicated factors. After 18 h
incubation, nitrite concentrations in the media were determined by a
microplate assay. 80 Wl aliquots of the culture media were incubated
with equal volumes of Griess reagent at room temperature for 10 min.
The absorbance at 540 nm was measured with an ELISA plate reader.
The nitrite concentrations were determined using dilutions of sodium
nitrite in water as a standard.
2.6. Data representation
Figures containing data from Northern blot and electrophoretic
mobility shift assay (EMSA) show typical results obtained from 3^5
independent experiments. Nitrite assays are presented for the same
experiments which were used to illustrate Northern blot data. Varia-
tions in cytokine-induced nitrite accumulation observed in repeated
experiments were below 20% for every cytokine or cytokine combina-
tion tested.
3. Results
Previous reports have demonstrated that TIMPs are ex-
pressed in endothelial cells [24^26]. We used MBE cells as a
model system to study the regulation of TIMP-1 and TIMP-3
expression in response to the proin£ammatory cytokines IL-
1L, TNFK, IFN-Q, and OSM. TIMP-2 was not included to
this study since it is expressed constitutively in endothelial
cells and, as in other cell types, its expression is not signi¢-
cantly in£uenced by cytokines and growth factors [24]. Both
in control and in cytokine-treated MBE cells we did not detect
mRNA for TIMP-4, the last of the known members of the
TIMP family.
In initial experiments the TIMP-1 expression pattern was
compared to cytokine-induced changes in mRNA levels of
VCAM-1 and iNOS, markers of endothelial cell activation.
Changes of TIMP-1 mRNA level observed in cytokine-stimu-
lated MBE cells resembled those observed for iNOS mRNA
(Fig. 1A) which, in turn, directly corresponded to the iNOS
activity measured as nitrite accumulation in the culture media
(Fig. 1B). The level of TIMP-1 transcript in control cells was
very low. Among single cytokines tested only IL-1L signi¢-
cantly up-regulated TIMP-1 mRNA level, whereas TNFK or
IFN-Q exhibited weaker, yet detectable stimulatory e¡ects
(compare Figs. 1A and 2, representing a prolonged TIMP-1
blot exposure time). The most dramatic stimulation of TIMP-
1 mRNA was observed when the combinations of IL-1L/
TNFK or TNFK/IFN-Q were used.
MBE cells constitutively expressed a high level of TIMP-3
mRNA. In contrast to the regulation of TIMP-1 expression,
the level of TIMP-3 mRNA signi¢cantly decreased in MBE
cells treated with IL-1L/TNFK and to some extent also with
IFN-Q/IL-1L (Fig. 2A). Because synergistic stimulation of
MBE cells with two major proin£ammatory cytokines (IL-
1L and TNFK) had the most profound e¡ects on TIMP-1
and TIMP-3 expression we studied this regulation in more
detail. Fig. 3 shows the dose-dependent e¡ect of IL-1L and
TNFK on the expression of TIMP-1 and TIMP-3. The cyto-
kines exhibited full synergistic e¡ects within the concentration
range 0.05^5 ng/ml: the highest stimulation of TIMP-1
mRNA as well as the strongest down-regulation of TIMP-3
mRNA level was observed in MBE cells treated with 5 ng/ml
of both IL-1L and TNFK. A decrease in concentration of
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either cytokine resulted in a marked decrease of their syner-
gistic action. Again, dose-dependent up-regulation of TIMP-1
and down-regulation of TIMP-3 expression correlated very
well with iNOS activity (Fig. 3B) providing further evidence
that reprogramming of TIMP-1 and TIMP-3 expression pat-
terns represents an additional characteristic of endothelial cell
activation in this experimental system.
Unexpectedly, OSM, which was shown to regulate TIMP-1
and/or TIMP-3 expression in ¢broblasts [27], hepatocytes [28],
chondrocytes [29] and synovial lining cells [30], did not sig-
ni¢cantly in£uence the levels of the corresponding mRNAs in
MBE cells (Fig. 2A). The absence of OSM e¡ects on TIMP-1
and TIMP-3 expression in MBE cells observed both at the
mRNA level and in transient transfection experiments (data
not shown) could be explained by the impaired mechanisms of
signal transduction for this cytokine. To test for this possibil-
ity we performed EMSA (Fig. 4) which clearly showed that in
MBE cells Stat3 is activated by OSM, whereas IFN-Q acti-
vated both Stat1 and Stat3, indicating that the functional
OSM receptor complexes are present in MBE cells. Therefore,
the tissue-speci¢c pattern of the cytokine-dependent regula-
tion of TIMP-1 and TIMP-3 expression appears to be unique
for endothelial cells in comparison with previously studied cell
systems [27^30].
In additional experiments we tested the pro¢le of TIMP-1
and TIMP-3 expression in rat astrocytes, representing a major
cell type in the brain perivascular tissue (Fig. 2B). In contrast
to brain endothelial cells, astrocytes expressed a signi¢cant
basal level of TIMP-1 mRNA and a markedly lower level of
TIMP-3 mRNA. Up-regulation of TIMP-1 mRNA level was
observed only in OSM- and TNFK-stimulated astrocytes but
no synergistic cooperation between the tested cytokines was
detected. The e¡ects of speci¢c cytokines on TIMP-3 expres-
sion in astrocytes were also di¡erent from those described for
MBE cells : in astrocytes, TNFK alone signi¢cantly decreased
TIMP-3 mRNA levels and TNFK in combination with IFN-Q
almost completely suppressed TIMP-3 expression. However,
in both MBE cells and astrocytes the tested proin£ammatory
cytokines generally exerted negative regulatory e¡ects on
TIMP-3 expression whereas TIMP-1 expression was up-regu-
lated.
4. Discussion
Proteolysis of subendothelial basement membrane during
leukocyte extravasation is an example of a highly coordinated
local ECM remodeling process. It involves spatial and tempo-
ral regulation of MMP synthesis and activity. Expression of
FEBS 21791 29-3-99
Fig. 1. Expression of TIMP-1 and endothelial cell activation markers VCAM-1 and iNOS in cytokine-treated MBE cells. A: MBE cells were
supplemented with fresh medium (RPMI with 2% FCS) and treated with IL-1L (5 ng/ml), TNFK (5 ng/ml), IFN-Q (200 u/ml) or the combina-
tions of cytokines as indicated. RNA was isolated after 18 h and subjected to Northern blot analysis with mTIMP-1, mVCAM-1, and miNOS
cDNA probes. The lower panel shows an ethidium bromide (EtBr)-stained blot photographed after RNA transfer. B: The culture media col-
lected before RNA isolation were used for nitrite measurement. Nitrite concentration was determined using Griess reagent after 18 h incubation
of approximately 6U106 MBE cells in 8 ml of medium.
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Fig. 3. Synergistic dose-dependent e¡ects of IL-1L and TNFK on the level of TIMP-1 and TIMP-3 expression in MBE cells. A: MBE cells
were supplemented with fresh medium (RPMI with 2% FCS) and treated with various concentration of IL-1L and TNFK as indicated. RNA
was isolated after 18 h and subjected to Northern blot analysis with mTIMP-1 and mTIMP-3 cDNA probes. The lower panel shows an ethidi-
um bromide (EtBr)-stained blot photographed after RNA transfer. B: The culture media collected before RNA isolation were used for nitrite
measurement. Nitrite concentration was determined using Griess reagent after 18 h incubation of approximately 6U106 MBE cells in 8 ml of
medium.
Fig. 2. Comparison of TIMP-1 and TIMP-3 expression pro¢les in cytokine-treated MBE cells (A) and astrocytes (B). MBE cells and astrocytes
were supplemented with fresh medium and treated with IL-1L (5 ng/ml), TNFK (5 ng/ml), IFN-Q (200 u/ml), OSM (25 ng/ml) or the combina-
tions of cytokines as indicated. RNA was isolated after 18 h and subjected to Northern blot analysis with mTIMP-1 and mTIMP-3 cDNA
probes. The lower panel shows an ethidium bromide (EtBr)-stained blot photographed after RNA transfer.
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several MMPs is up-regulated by IL-1L and TNFK in endo-
thelial cells [24], macrophages and T cells [7,31]. Human T cell
activation results in the stimulation of expression of both
gelatinases (MMP-9 and MMP-2) [32]. Furthermore, in endo-
thelial cells MMP-2 expression is induced by T cell adhesion
and requires binding of the T cell very late activation antigen
4 (VLA-4) to VCAM-1 [33]. These data indicate that leuko-
cyte activation and endothelial cell activation trigger increased
local MMP synthesis, including synthesis of pro-gelatinases
which, in their active forms, are able to degrade major sub-
endothelial basement membrane components including colla-
gen types IV and V.
In this paper we show that major proin£ammatory cyto-
kines cause a dramatic reprogramming of the TIMP-1 and
TIMP-3 expression pro¢les in endothelial cells. The most
spectacular e¡ects are mediated by two key proin£ammatory
cytokines: IL-1L and TNFK. In MBE cells they synergistically
repress TIMP-3 expression, whereas the opposite regulation is
detected for TIMP-1. Fully synergistic action of these cyto-
kines could be observed within a concentration range of 0.05^
5 ng/ml, which strongly suggests that in vivo precise, cytokine-
and concentration-dependent mechanisms regulate levels of
these endogenous MMP inhibitors and, indirectly, microvas-
cular basement membrane proteolysis.
The opposite regulation of TIMP-1 and TIMP-3 expression
indicates that these proteins may play distinct roles in the
regulation of microvascular ECM proteolysis. In contrast to
other characterized TIMP family proteins which are soluble,
TIMP-3 is associated with ECM [34]. TIMP-3 deposited into
the microvascular basement membrane may, therefore, pro-
tect it against proteolytic degradation mediated by MMPs.
Under normal conditions, characterized by high TIMP-3
and low TIMP-1 expression, the dynamic balance between
synthesis and degradation of the basement membrane is main-
tained. In activated endothelial cells TIMP-3 expression is
down-regulated and proteolysis of microvascular ECM may
be subsequently enhanced. Simultaneous stimulation of
TIMP-1 expression observed in response to in£ammatory cy-
tokines may, in turn, provide a compensatory mechanism to
prevent uncontrolled activation of MMPs at sites of in£am-
mation and tissue damage.
Changes in the pro¢le of TIMP-1 and TIMP-3 expression
in cytokine-stimulated endothelial cells may also enhance cell
surface-associated activation of ECM proteolysis mediated by
MT-MMP-1. MT-MMP-1 is expressed in vascular endothelial
cells [35]. On the cell surface MT-MMP-1 acts as a broad-
spectrum ECM proteinase. Recently, it has been shown that
MT-MMP-1 may also initiate a cascade activation of other
MMPs, including gelatinases [36]. Because MT-MMP-1 is ef-
¢ciently inhibited by TIMP-3, but not TIMP-1 [37], reprog-
ramming of TIMP-1 and TIMP-3 expression during endothe-
lial cell activation could result in the local increase in MT-
MMP-1 activity.
The newly described ability of TIMP-3 to inhibit cell sur-
face-associated TNFK converting enzyme (ADAM-17) [9] sug-
gests that the down-regulation of TIMP-3 expression level
may also result in the acceleration of pro-TNFK processing
and further ampli¢cation of local in£ammation. Interestingly,
we show that TNFK (alone or in combination with IFN-Q) is
also capable of inhibiting TIMP-3 expression in primary as-
trocytes, with TIMP-1 expression being simultaneously stimu-
lated. The coordinated regulation of TIMP-1 and TIMP-3
expression described in this paper for both endothelial cells
and astrocytes could, therefore, represent an important mech-
anism involved in the brain ECM proteolysis under patholog-
ical conditions associated with in£ammation, such as multiple
sclerosis (MS); especially the TNFK-mediated stimulation of
MMPs expression and synthesis is considered to be an impor-
tant link between the proin£ammatory cytokine network and
the local increase of the proteolytic activity observed in MS
and several other neurodegenerative diseases [38].
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Fig. 4. IFN-Q and OSM activate Stat factors in MBE cells and astrocytes. MBE cells and primary rat astrocytes were stimulated with IFN-Q
(200 U/ml) and OSM (25 ng/ml) for 15 min. Cells were collected and nuclear extracts were prepared. 5 Wg of protein was incubated with the
32P-labelled SIE probe. The DNA-protein complexes were separated on a native 4.5% polyacrylamide gel. After drying the gel was exposed to
an X-ray ¢lm.
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